We have previously reported that endometrial expression of matrix metalloproteinase (MMP)-26 mRNA comes to a maximum in the early secretory phase. Since tissue inhibitor of metalloproteinase (TIMP)-4 is a potent inhibitor of MMP-26, the objective of this study was to identify the pattern of TIMP-4 mRNA expression in the normal endometrial cycle. We also evaluated hyperplastic, pre-malignant (atypical hyperplasia) and malignant endometrial tissue. Endometrial TIMP-4 mRNA was localized in tissue sections using in situ hybridization, and quantified in tissue extracts using real-time PCR. Estrogen receptor a (ERa) was assayed in the same set of samples using immunohistochemistry. In situ hybridization demonstrated TIMP-4 mRNA in the stroma of both normal and pathological tissues. TIMP-4 mRNA increased in the proliferative phase to a maximum in the early secretory phase, and then decreased in the late part of the cycle. Expression was comparable in normal and hyperplastic (including atypical) endometrial samples, whereas lower levels were detected in malignant tumours. Since this general pattern of expression suggests estrogen dependence, we evaluated ERa in our samples. Tissue sections from the normal proliferative phase, hyperplasia and pre-malignant atypical hyperplasia tissue stained strongly for ERa, whereas weak staining was seen in the secretory phase and in malignant tumours. Thus, low level of ERa was accompanied by down-regulated TIMP-4 mRNA, supporting the hypothesis that ERa contributes to regulation of the TIMP-4 gene. In addition, we identified a putative estrogen response element (ERE) in the promoter region of the TIMP-4 gene at position 2 930 to 2 916. Similarities in the cyclic patterns of TIMP-4 mRNA and MMP-26 mRNA, together with the fact that TIMP-4 is a potent inhibitor of MMP-26, suggest a functional relationship, and furthermore a role in human implantation.
Introduction
The activity of matrix metalloproteinases (MMP) is regulated locally within tissues by specific inhibitors, belonging to the tissue inhibitor of metalloproteinase (TIMP) family. Currently, four mammalian TIMP (TIM-1, -2, -3, -4) have been identified (Welgus and Stricklin, 1983; Stetler-Stevenson et al., 1989; Apte et al., 1995; Greene et al., 1996) . They form tight 1:1 complexes with activated MMP, inhibiting their enzymatic activity. Specificity and affinity of the TIMP for individual MMP vary (Woessner, 1991; Gomis-Ruth et al., 1997; Brew et al., 2000) .
The TIMP-4 gene has high sequence identity with the TIMP-2 gene (Greene et al., 1996) . Also, TIMP-4 and TIMP-2 have functional characteristics in common, i.e. they bind MMP-2 within the same region (Stratmann et al., 2001) , and they are the strongest known inhibitors of MMP-19 (Stracke et al., 2000) . Kinetic studies of the inhibitory capacity of TIMP-4 revealed IC 50 to be 19, 3, 45, 8, 83 and 0.4 nmol/l for MMP-1, -2, -3, -7, -9 and -26 respectively, thus demonstrating that TIMP-4 has highest affinity for MMP-26 among these MMP (Liu et al., 1997; Zhang et al., 2002) .
TIMP-2 is constitutively and widely expressed, whereas TIMP-1 and TIMP-3 are expressed in response to signals such as cytokines, hormones and mitogens (Stetler-Stevenson et al., 1990; Lotz and Guerne, 1991; Mann et al., 1991; Sato et al., 1991; Wick et al., 1994) . Tissue expression of TIMP-4 differs from the other members of the family by being more limited. The highest level of expression is reportedly in the heart, with much lower levels in the kidney, pancreas, colon and testes (Greene et al., 1996) .
Both MMP and TIMP are expressed at low levels in most adult tissues under physiological conditions. Exceptions with higher expression include endometrial tissue in the menstrual phase, mammary gland involution, and pathophysiological conditions such as wound healing and tumour progression (Birkedal-Hansen, 1995) .
The monthly cycle of the endometrium involves menstrual desquamation followed by re-growth and differentiation. Endometrial expression of many MMP is associated with tissue degradation during menstruation, whereas others are involved in tissue remodelling during re-growth (Curry and Osteen, 2001) . are all mainly or exclusively associated with the menstrual phase of the endometrial cycle Rodgers et al., 1994; Marbaix et al., 1995; Goffin et al., 2003) , whereas MMP-2 (Rodgers et al., 1994) and MMP-19 (Goffin et al., 2003) are constitutively expressed over the cycle. In contrast to most MMP, which are expressed by stromal cells, MMP-7 is mainly or exclusively found in epithelial cells (Rodgers et al., 1993; Rawdanowicz et al., 1994; Rodgers et al., 1994; Wilson and Matrisian, 1996) .
MMP-26 is a novel metalloproteinase, which shares functional and structural similarities with MMP-7 (de Coignac et al., 2000; Park et al., 2000; Uria and Lopez-Otin, 2000; Marchenko et al., 2001) . We recently reported that endometrial MMP-26 mRNA is localized in epithelial cells, and that expression is maximal in the early secretory phase (Pilka et al., 2003) .
Endometrial expression of TIMP-1 and -3 is typically increased in the late secretory and menstrual phases, whereas TIMP-2 is constitutively expressed over the cycle Rodgers et al., 1994; Zhang and Salamonsen, 1997; Maatta et al., 2000; Goffin et al., 2003) . Localization of these TIMP is stromal, but TIMP-3 is also found in epithelial cells in the proliferative phase (Rodgers et al., 1994; Maatta et al., 2000) .
TIMP-4 was reported in the endometrium using immunohistochemistry, but no significant cyclical pattern was demonstrated Tunuguntla et al., 2003) .
Over-expression of MMP has been associated with malignant tumours of various origins (Egeblad and Werb, 2002) . Endometrial tumours have been reported to have enhanced production of MMP-1, -2, -7, -9, MT1-MMP, TIMP-1, -2 and -3, either in the tumour cells or in the tumour stroma (Takemura et al., 1992; Soini et al., 1997; Iurlaro et al., 1999; Ueno et al., 1999; Maatta et al., 2000; Di Nezza et al., 2002) .
Expression of the TIMP-4 mRNA has not previously been reported in normal, hyperplastic, or malignant endometrial tissue. Thus, we used in situ hybridization and real-time PCR for localization and quantification of TIMP-4 mRNA in these tissues. In addition, the cyclic pattern of TIMP-4 mRNA was compared to those of MMP-26 mRNA and estrogen receptor a (ERa). The TIMP-4 gene was searched upstream from the coding region for a sequence with high homology to the consensus sequence of an estrogen response element (ERE).
Materials and methods

Tissue sampling and processing
Samples of normal, hyperplastic and malignant endometrial tissue were obtained at diagnostic curettage or at hysterectomy. Normal endometrial tissue was obtained from patients operated for benign non-endometrial pathology (e.g. leiomyoma, cervical dysplasia, uterine prolapse etc.) and who were of mean age 43 (range 34-45) years. Tissue samples from patients receiving steroid treatment were not included in the study. All specimens were classified according to an ideal 28 day reproductive cycle as early (n ¼ 8), mid (n ¼ 6) and late (n ¼ 7) proliferative phase, early (n ¼ 4), mid (n ¼ 4) and late (n ¼ 4) secretory phase, pre-menstrual (n ¼ 3), and menstrual phase (n ¼ 3) (Hendrickson and Kempson, 1980; Noyes, 1950) .
Endometrial samples with hyperplasia were classified as: simple (n ¼ 6), complex (n ¼ 3), or complex with atypia (n ¼ 6). Patients were of mean age 53 (range 42-78) years. All the malignant samples had endometrioid histology and were classified as: well (n ¼ 7), intermediately (n ¼ 7) and poorly (n ¼ 6) differentiated. Patients were of mean age 65 (range 40-86) years. Samples were collected at the Department of Gynaecology and Obstetrics, and sampling was approved by the Review Board for studies in Human Subjects at the Lund University Hospital. One part of every tissue sample was immediately cut into pieces (maximum 4 £ 4 £ 4 mm), frozen on dry ice and subsequently stored at 2808C until further processed for in situ hybridization and real-time PCR. The other part was formalin-fixed and paraffinembedded for histopathological examination and immunohistochemistry.
Extraction of mRNA
One portion of each frozen sample was disintegrated with a microdismembrator and weighed. Total RNA was extracted in 1 ml of Trizol Reagente (Life Technologies, Sweden) per 50 mg of tissue and subsequently centrifuged for 15 min at 48C and 12 000 g. The supernatant was incubated for 10 min at room temperature before 0.2 ml of chloroform per 50 mg tissue was added. Samples were vortexed for 15 s and subsequently centrifuged for 15 min at 48C and 12 000 g. The chloroform phase was mixed with isopropanol and salt solution (Na-citrate 0.8 mol/l and NaCl 1.2 mol/l) 0.75 ml per 50 mg tissue, and kept at 2208C for 60 min. After thawing, samples were centrifuged for 30 min at 48C and 12 000 g. The pellet was dried with 75% ethanol, 1 ml per 50 mg of tissue. The RNA pellet was air-dried and diluted in RNAse-free water. The total amount of RNA was assayed spectrophotometrically.
The other portion of the endometrial samples was used for in situ hybridization.
Preparation and labelling of cRNA probes
For the human TIMP-4 mRNA, a probe corresponding to 440 nt (231-670) was used, GenBank accession nm_003256 (Greene et al., 1996) . DNA templates were generated by PCR amplification from the human TIMP-4 cDNA using bipartite primers consisting of either a modified T7 RNA promoter and a downstream gene-specific sequence (GTGCCGTCAACATGCTTCATA) (anti-sense) or a modified T3 RNA promoter and an upstream gene-specific primer (GTTCCGGCCAGTGCAGACCCT) (sense). Single-stranded RNA probes were prepared from cloned matrix metalloproteinase cDNA. PCR reactions using 1 ng human TIMP-4 cDNA, 1 mg primers, 200 mmol/l dNTP, 3 mmol/l MgCl 2 , 10 mmol/l Tris, pH 8.3, 50 mmol/l KCl, 2.5 IU Taq polymerase (Invitrogen) were amplified at 958C for 1 min, 628C for 1 min and 728C for 1 min for 30 cycles with a final extension at 728C for 10 min. Full-length size of transcripts was verified with electrophoresis. DNA templates were purified from agarose gels using QIAquick Gel Extraction Kit (250) (Qiagen). Complementary RNA (cRNA) probes were transcribed from 5 ng of gel-purified DNA template using [ 
Quantification of mRNA with real-time PCR
Aliquots of mRNA (500 ng) from each sample were reverse-transcribed using superscript II according to the manufacturer's manual (Invitrogen, USA). Subsequently, after dilution of the cDNA 5-fold, 3 ml cDNA was amplified by real-time PCR with 1 £ TaqMan universal PCR mastermix (Applied Biosystems, USA). A TIMP-4 Assay on Demand Kit from Applied Biosystems (primer set # Hs00162784_m1) was used. The TaqMan probe included the nucleotide (nt) region 122-146. For b-actin, 200 mmol/l of each primer and 1.25 pmol/l of probe were used and primers were designed using the Primer Express software (Applied Biosystems). b-Actin was used as a housekeeping gene to normalize the results; the primers for b-actin were: b-actin-FW: 5-CTGGCTGCTGACCGAGG-3 and b-actin-RW: 5-GAAGGT-CTCAAACATGATCTGGGT-3; and the probe was: b-actin-TM: 6FAM5 0 -CCCTGAACCCCAAGGCCAACCG-3 0 TAMRA. Each sample was analysed in duplicate using ABI prism 7000 (Applied Biosystem). The PCR amplification was related to a standard curve.
Localization of mRNA
One piece of frozen tissue from each sample was processed for in situ hybridization.
Cryostat sections, 14 mm thick, were collected on siliconized glass slides and stored at 2808C.
The radiolabelled cRNA probe was transcribed from a template using 20 mmol/l [ 35 S]UTP (800 CI/mmol). The RNA polymerases used were T3 for sense and T7 for antisense. Prior to hybridization, tissue sections were pretreated as described (Young, 1990) .
Sections were thawed directly in 4% formaldehyde in phosphate-buffered saline (PBS) and fixed for 5 min, rinsed twice in PBS, and acetylated in 0.1 mol/l triethanolamine-HCl, 0.25% acetic anhydride, pH 8 for 10 min. Sections were then rinsed twice in 2 £ saline-sodium citrate (SSC), dehydrated in ethanol 70% for 1 min, 80% for 1 min, 95% for 2 min, 100% for 1 min, and 95% for 1 min, prior to air drying. Hybridization with cRNA was performed as described by Cox et al. (1984) ) and Whitfield et al. (1990) .
[ 35 S]cRNA probes were denatured at 658C for 5 min and placed on ice for 5 min. Final hybridization buffer, with 1 £ 10 6 cpm of denatured [ 35 S]cRNA probe per 50 ml, consisted of 20 mmol/l Tris-HCl (pH 7.4), 1 mmol/l EDTA (pH 8.0), 300 mmol/l NaCl, 50% formamide, 10% dextrasulphate, 1 £ Denhardt's, 25 g/l yeast tRNA, 100 mg/l salmon sperm DNA, 250 mg/l total yeast RNA (fraction XI), 100 mmol/l dithiothreitol (DTT), 0.1% sodium thiosulphate, and 0.1% sodium dodecyl sulphate.
Hybridization buffer (70 ml/15 cm 2 ) was applied to tissue sections on each slide and covered with untreated glass cover slips. Slides were then incubated at 568C in chambers humidified with 2 £ SSC with 50% formamide for 24 h. After hybridization, slides were cooled to room temperature, and coverslips were floated off the slides in 4 £ SSC. Slides were then rinsed in four rounds of 4 £ SSC followed by immersion in 20 mg/l RNAse A at 378C for 30 min. Sections were desalted in graded SSC solutions and washed twice in 0.1 £ SSC at 658C for 30 min. Sections were air-dried after dehydration in graded ethanol solutions.
After hybridization, slides were incubated with Kodak Bio-Max MR film for 1-4 days. Slides were then coated with undiluted nuclear track emulsion (NTB-3, Kodak) and following exposure for 4-5 weeks at 48C, slides were developed in D-19 (Kodak) and counterstained with 1% Toluidine Blue.
All slides were evaluated by two independent observers (R.P. and H.D.). In order to allow semiquantitative evaluation, the intensity of the signal was graded as negative (0) when the signal was indistinguishable from the background; faint (1) when intensity was distinguishable from the background; moderate (2) when signal intensity was less than half-maximal; strong (3) when the signal was more than half-maximal; very strong (4) when the signal was maximal.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were treated with 10 mmol/l citrate buffer pH 6.0 in a microwave oven at 550 W for 17 min for antigen retrieval (Shi et al., 1991) . Immunostaining was performed in an automated immunostainer, TechMate 500 (Ventana Biotek, USA) using the biotinstreptavidin-peroxidase system with diaminobenzidine as the chromogen. ChemMatee Detection Kit (haematoxylin) was used for counterstaining (Dao, Denmark). The primary antibody was a monoclonal for the estrogen receptor a (ERa; Clone 1D5; DakoCytomation, Denmark) diluted 1:100. Immunostaining was evaluated by two independent observers (H.D. and R.P.). The number of positive nuclei was semiquantitatively given as 0, 1 (,25%), 2 (25-75%) and 3 (,75%).
Statistical methods
Results are presented as median and percentiles of groups. Mann-Whitney U-test was used to evaluate the significance of differences between groups. 
Results
The TIMP-4 mRNA signal was evenly distributed within stroma in normal and hyperplastic endometrial samples (Figures 1 and 2) . In contrast, the stromal signal was unevenly distributed in malignant samples. No signal was detected in normal epithelial cells or in tumour cells. Sections hybridized with the sense probe had no signal.
Intensity of the hybridization signal was evaluated using a semiquantitative scoring system (see Materials and methods). TIMP-4 mRNA signal intensity was generally low, but nevertheless, a clear cyclical pattern emerged (Figure 3) . The signal increased during the proliferative phase to a maximum in the early secretory phase, and then decreased gradually through the mid and late secretory phases to lowest levels in the menstrual phase. Hyperplastic samples had similar TIMP-4 mRNA signal intensity as samples from the early part of the cycle. The signal was sometimes strong, sometimes absent in well-differentiated samples, and sometimes weak but mostly absent in poorly differentiated samples.
TIMP-4 mRNA was quantified by real-time PCR in extracts of samples from the same tissue specimens as used in in situ hybridization. Results were normalized to b-actin mRNA. A representative real-time experiment is shown in Figure 4 . The PCR product is difficult to visualize with gel electrophoresis, since TaqMan is using very short fragments. Real-time PCR data demonstrated a similar cyclic pattern of TIMP-4 mRNA as the semiquantitative in situ data, i.e. an increase from the early proliferative phase to a peak in the early secretory phase, and then a gradual decrease to the menstrual phase ( Figure 5 ). The amount of TIMP-4 mRNA was not different between normal and hyperplastic tissue samples (with and without atypia), but was lower in malignant tumour samples.
Nuclear staining for ERa was evaluated in the complete set of tissue samples by semiquantitative assessment of specific immunostaining. Stromal staining for ERa in the normal cycle was high in the proliferative phase and reduced in the secretory phase. It was also high in hyperplastic (with or without atypia) but low in malignant tissue samples. Within the malignant group, staining for ERa was gradually reduced with loss of histological differentiation to be absent in poorly differentiated tumours (Figure 6 ).
Discussion
TIMP-4 mRNA has been identified in a variety of normal human tissues, e.g. heart, kidney, pancreas, colon, testes, cytotrophoblast (Greene et al., 1996; Zhang et al., 2002) , but has previously not been reported in the endometrial tissue. We found TIMP-4 mRNA in the stroma of normal as well as pathological human endometrial tissues. Also, the TIMP-4 protein has been immunohistologically localized in endometrial tissue Tunuguntla et al., 2003) . In contrast to our in situ hybridization data, these authors found the protein in both stromal and epithelial cells. This may represent release of TIMP-4 protein from stromal to epithelial cells. Taken together with the findings of others, all known human TIMP have now been reported in endometrial tissue. TIMP-1 mRNA and TIMP-2 mRNA have been localized in stromal and vascular endothelial cells, whereas TIMP-3 mRNA was found both in stromal and epithelial cells (Rodgers et al., 1994; Maatta et al., 2000) .
The expression of TIMP-1 and TIMP-3 mRNA was typically higher in the late secretory and menstrual phases than in the proliferative and early secretory phases (Rodgers et al., 1994; Maatta et al., 2000; Goffin et al., 2003) . In contrast, the level of TIMP-2 mRNA was stable over the menstrual cycle. No quantitative data have been reported on the cyclical pattern of TIMP-4 protein in endometrial tissue, but immunostaining data suggest highest protein content in the early and mid parts of the secetory phase Tunuguntla et al., 2003) . Thus, among TIMP family members, the cyclical pattern of expression is unique for TIMP-4. Up-regulation pre-menstrually of TIMP-1 and -3 versus at midcycle of TIMP-4 suggests different regulatory mechanisms. In contrast, TIMP-2 appears to be constitutively expressed during the cycle.
The cyclic pattern of TIMP-4 mRNA in the endometrial stroma, with a peak in the early secretory phase, mimics very closely that of Figure 3 . Semiquantitative evaluation of signal intensity in endometrial tissue sections (n ¼ 71) hybridized to the TIMP-4 antisense probe. Tissue samples were classified as early (EP; n ¼ 7), mid (MP; n ¼ 6) and late (LP; n ¼ 7) proliferative phase, early (ES; n ¼ 4), mid (MS; n ¼ 4) and late (LS; n ¼ 7) secretory phase, and the menstrual (M; n ¼ 3) phase. Pathological samples were classified as hyperplasia without atypia (Hyp; n ¼ 7); hyperplasia with atypia (Atyp; n ¼ 6); well (Well; n ¼ 7), intermediately (Inter; n ¼ 7) and poorly (Poor; n ¼ 6) differentiated cancer. Intensity of the signal was classified as negative (0), faint (1), moderate (2), strong (3), or very strong (4) on a relative scale. Intensity increased from the early proliferative phase to a maximum in the early secretory phase (P , 0.0001), and then decreased from the early secretory phase to the menstrual phase (P , 0.0001). Intensity of the signal was higher in normal (P , 0.0001) and hyperplastic (Hyp þ Atyp) (P ¼ 0.001) than in malignant (Well þ Inter þ Poor) samples. Normal and hyperplastic samples were not different. Box plot showing median, 25th and 75th percentiles.
TIMP-4 in the human endometrium MMP-26 mRNA in endometrial epithelium (see Figure 7) (Pilka et al., 2003) . Co-expression of MMP-26 and TIMP-4 is likely to have physiological relevance, since TIMP-4 has highest inhibitory capacity towards MMP-26 (Stracke et al., 2000; Zhang et al., 2002) . Timing in the cycle suggests that MMP-26 is relevant to the implantation process, and co-regulation of its main inhibitor TIMP-4 is important for controlled MMP-26 activity. The enzyme is likely to reach peak concentration in the endometrial epithelium at the time of blastocyst adhesion and penetration. One potential function for MMP-26 may be to activate embryonic pro-MMP-9, and active MMP-9 can provide a crucial proteolytic capacity during penetration of the epithelial barrier (Librach et al., 1991; Zhang et al., 2003) . The high inhibitory capacity of TIMP-4 for MMP-26 suggests one level of protecting the stroma against proteolytic activity, i.e. epithelial MMP-26 may be neutralized by TIMP-4 if released in the stroma. Thus, TIMP-4 might be ascribed a function in human implantation, similar to what has been observed in mouse implantation (Zhang et al., 2003) .
TIMP-4 mRNA has previously been localized in tumour cells or in the vasculature in a variety of tumours such as brain, breast and renal cancer and choriocarcinoma (Greene et al., 1996; Groft et al., 2001; Hagemann et al., 2001; Hurst et al., 2001; Jiang et al., 2001; Zhang et al., 2002) . In contrast, we localized TIMP-4 mRNA in the stromal compartment of hyperplastic, pre-malignant and malignant endometrial tissues. This discrepancy emphasizes the substantial differences between tumour types in utilizing a specific enzyme or inhibitor. An immunohistochemical study of endometrial cancer found TIMP-4 in the carcinoma cells, particularly in the invading cells, as well as in vascular endothelial cells, smooth muscle cells and inflammatory cells of the stroma (Tunuguntla et al., 2003) .
Also, we found that the amount of TIMP-4 mRNA is not different between normal and hyperplastic samples, but is lower in endometrial cancer. Levels were not different between the histological groups of malignant tumours. Tunuguntla et al. (2003) also observed no significant difference in the staining intensity for TIMP-4 protein between endometrial tumours of different grades. In contrast, expression of TIMP-1, -2 and -3 was increased in endometrial cancer, but was negligible in hyperplasia (Maatta et al., 2000) . Thus, the unique expression pattern for TIMP-4 observed in the normal cycle is accompanied by an equally unique expression pattern in pathological endometrial conditions. While TIMP-1 mRNA was Figure 3 . Expression increased from the early proliferative phase to a maximum in the early secretory phase (P ¼ 0.0002), and decreased from the early secretory to the menstrual phase (P ¼ 0.0002). TIMP-4 mRNA levels were higher in normal (P ¼ 0.0005) and hyperplastic samples (Hyp þ Atyp) (P ¼ 0.0002) than in malignant (Well þ Inter þ Poor) samples. Levels were not different between normal and hyperplastic samples, and also not between the histological groups of malignant tumours. Box plot showing median, 25th and 75th percentiles. Figure 3 . The number of positive nuclei was estimated and given a score of 0, 1, 2 or 3. The number of ERa positive nuclei was higher in the proliferative than in the secretory phase of the normal cycle (P , 0.0001), and higher in hyperplastic than in malignant tissue samples (P , 0.0001). Box plot showing median, 25th, and 75th percentiles.
TIMP-4 in the human endometrium localized in the tumour stroma, TIMP-2 and TIMP-3 mRNA were found in both stromal and tumour cells (Maatta et al., 2000) . Thus, stromal distribution of TIMP-4 mRNA in endometrial tumours is similar to that of TIMP-1 mRNA.
Peak levels at midcycle and higher levels in hyperplastic than in malignant endometrial samples suggest estrogen regulation of TIMP-4 mRNA. Transcriptional regulation by estrogenic compounds is mediated by the nuclear estrogen receptors (ER), which, after dimerization, function as transcription factors and interact with estrogen response elements (ERE) within the promoter region of target genes.
In order to compare the cyclic pattern of TIMP-4 mRNA with that of ERa in the endometrial stroma, we assessed immunohistochemical staining for ERa in paraffin sections of the same set of endometrial samples. We found ERa staining to be maximal in the proliferative phase of the normal cycle and in hyperplasia. Low levels were detected in the secretory phase of the normal cycle, and in malignant samples. This pattern is in agreement with the reports by others (Punnonen et al., 1993; Kato et al., 1999; Matsuzaki et al., 1999; Kounelis et al., 2000; Utsunomiya et al., 2000; Lecce et al., 2001; Mertens et al., 2001) . Since the stromal content of ERa was maximal throughout the proliferative phase, increment of the TIMP-4 gene transcription may require additional regulatory factor(s), e.g. the midcycle peak of estradiol. Downregulation of TIMP-4 mRNA in the mid and late secretory phase follows down-regulation of ERa by progesterone. High levels of TIMP-4 mRNA in the pre-malignant cases, i.e. atypical hyperplasia, may in fact suggest that down-regulation of TIMP-4 in malignancy is not a direct effect of the malignant process, but is rather secondary to down-regulation of ERa, since ERa is high in the pre-malignant cases.
Studies of estrogen responsive genes have revealed a common sequence motif representing the ERE, with high affinity binding of dimerized ER (Walker et al., 1983; Klein-Hitpass et al., 1986; Peale et al., 1988) . Experiments with constructs, in which the ERE sequence was inserted upstream of a reporter gene, confirmed that a 13 bp inverted repeat was an essential element for estrogen responsiveness (Klein-Hitpass et al., 1988) . A consensus ERE sequence with stable ER binding has been reported (Figure 8 ) (Seiler-Tuyns et al., 1986; Klein-Hitpass et al., 1988; Driscoll et al., 1998) . Substitutions in this optimal sequence decrease the affinity for ER dimers. We searched the promoter region of the TIMP-4 gene for a potential ERE (Young et al., 2002) . A sequence with homology to the consensus ERE is present at position 2 930/2 916 (Figure 8 ). This sequence has two substitutions within the core but they are balanced by guanines in the immediate flanking regions. Even with two substitutions in the core sequence, the ERE is able to bind ER homodimers (Driscoll et al., 1998) . These data predict that the identified sequence within the TIMP-4 promoter region has high ER binding. (Young et al., 2002) , which contains a putative estrogen response element (ERE) at position 2930/-916 (enlarged). Adjacent to this site is a myogenin transcription factor-binding site. (B) Sequence with optimal estrogen receptor (ER) binding capacity (Driscoll et al., 1998) . The core consensus is underlined. The bases in the ERE are numbered starting from the nucleotide at the centre, with negative numbers upstream and positive numbers downstream. Sequence 2930 to 2916 has high homology with the consensus sequence. With only two substitutions in the core consensus, at þ 5 and þ 6, the identified ERE should be able to bind ER homodimers (Driscoll et al., 1998) .
